Tag Archives: www.ipftoday.com

August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Posted on September 28, 2013 by IPF Today

1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF). 2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization. Evidence rating level: 1 (Excellent) Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

July 29 2013 – UVM hosts conference on revolutionary cell therapies to treat deadly lung diseases

Posted on September 28, 2013 by IPF Today

On Monday, July 29, 2013, leading lung disease researchers from around the globe will participate in the fifth biennial “Stem Cells and Cell Therapies in Lung Biology Conference” at the University of Vermont (UVM). Since the meeting’s initiation eight years … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 15 2013 – Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting

Posted on September 28, 2013 by IPF Today

Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the  company has received an Issue Notification from the U.S. Patent and Trademark  Office for a patent application covering the company’s drug candidate  CGEN-25009. CGEN-25009 is intended for the … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

July 11 2013 – ProMetic’s Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

Posted on September 28, 2013 by IPF Today

LAVAL, QUEBEC–(Marketwired – July 11, 2013) – ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that its lead drug candidate PBI-4050, is on track to enter the clinical trial program starting in September 2013. During the … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 7 2013 – University of Washington’s first double lung transplant doing great 2 decades later

Posted on September 28, 2013 by IPF Today

The first person to get a double lung transplant at the University of Washington is still breathing strong 20 years later. Ken Price had been living with cystic fibrosis since he was 1 year old, KOMO-TV reports. He was the … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 2 2013 – New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

Posted on September 11, 2013 by IPF Today

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients. The study also found that certain proteins found in lung fluid can help predict whether a patient’s … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

June 28 2013 – Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials

Posted on September 11, 2013 by IPF Today

Summary Background Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic pulmonary fibrosis (IPF) and is considered a risk factor for development of IPF. Retrospective studies have shown improved outcomes in patients given anti-acid treatment. The aim of this … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

June 24 2013 – Verona Pharma confirms 1st patient dosed with VRP700

Posted on September 11, 2013 by IPF Today

StockMarketWire.com – Verona Pharma said the first patient in a clinical trial to further evaluate the efficacy of VRP700 as a novel treatment for chronic severe cough has been dosed with the drug.  It was anticipated that data from this … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

June 12 2013 – GPs urged to suspect pulmonary fibrosis in older patients with persistent cough

Posted on September 11, 2013 by IPF Today

    NICE is urging GPs to be alert to the clinical features of idiopathic pulmonary fibrosis (IPF) and refer patients who may have the condition promptly, in new guidance aimed at speeding up diagnosis and treatment for the condition. … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

May 24 2013 – Reflux Medicine Boosts Survival in Lung Disease

Posted on June 12, 2013 by IPF Today

PHILADELPHIA  —  Survival in idiopathic pulmonary fibrosis (IPF) improved significantly in patients treated with proton pump inhibitors (PPIs), adding to a body of literature supporting PPI benefits in IPF, investigators in a retrospective review concluded. Patients treated with PPIs had … Continue reading →

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment